Back to Search Start Over

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.

Authors :
Liu, Albert Y
Liu, Albert Y
Cohen, Stephanie E
Vittinghoff, Eric
Anderson, Peter L
Doblecki-Lewis, Susanne
Bacon, Oliver
Chege, Wairimu
Postle, Brian S
Matheson, Tim
Amico, K Rivet
Liegler, Teri
Rawlings, M Keith
Trainor, Nikole
Blue, Robert Wilder
Estrada, Yannine
Coleman, Megan E
Cardenas, Gabriel
Feaster, Daniel J
Grant, Robert
Philip, Susan S
Elion, Richard
Buchbinder, Susan
Kolber, Michael A
Liu, Albert Y
Liu, Albert Y
Cohen, Stephanie E
Vittinghoff, Eric
Anderson, Peter L
Doblecki-Lewis, Susanne
Bacon, Oliver
Chege, Wairimu
Postle, Brian S
Matheson, Tim
Amico, K Rivet
Liegler, Teri
Rawlings, M Keith
Trainor, Nikole
Blue, Robert Wilder
Estrada, Yannine
Coleman, Megan E
Cardenas, Gabriel
Feaster, Daniel J
Grant, Robert
Philip, Susan S
Elion, Richard
Buchbinder, Susan
Kolber, Michael A
Source :
JAMA internal medicine; vol 176, iss 1, 75-84; 2168-6106
Publication Year :
2016

Abstract

ImportanceSeveral randomized clinical trials have demonstrated the efficacy of preexposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) acquisition. Little is known about adherence to the regimen, sexual practices, and overall effectiveness when PrEP is implemented in clinics that treat sexually transmitted infections (STIs) and community-based clinics serving men who have sex with men (MSM).ObjectiveTo assess PrEP adherence, sexual behaviors, and the incidence of STIs and HIV infection in a cohort of MSM and transgender women initiating PrEP in the United States.Design, setting, and participantsDemonstration project conducted from October 1, 2012, through February 10, 2015 (last date of follow-up), among 557 MSM and transgender women in 2 STI clinics in San Francisco, California, and Miami, Florida, and a community health center in Washington, DC. Data were analyzed from December 18, 2014, through August 8, 2015.InterventionsA combination of daily, oral tenofovir disoproxil fumarate and emtricitabine was provided free of charge for 48 weeks. All participants received HIV testing, brief client-centered counseling, and clinical monitoring.Main outcomes and measuresConcentrations of tenofovir diphosphate in dried blood spot samples, self-reported numbers of anal sex partners and episodes of condomless receptive anal sex, and incidence of STI and HIV acquisition.ResultsOverall, 557 participants initiated PrEP, and 437 of these (78.5%) were retained through 48 weeks. Based on the findings from the 294 participants who underwent measurement of tenofovir diphosphate levels, 80.0% to 85.6% had protective levels (consistent with ≥4 doses/wk) at follow-up visits. African American participants (56.8% of visits; P = .003) and those from the Miami site (65.1% of visits; P < .001) were less likely to have protective levels, whereas those with stable housing (86.8%; P = .02) and those reporting at least 2 condomless anal sex partners in the past 3 months

Details

Database :
OAIster
Journal :
JAMA internal medicine; vol 176, iss 1, 75-84; 2168-6106
Notes :
application/pdf, JAMA internal medicine vol 176, iss 1, 75-84 2168-6106
Publication Type :
Electronic Resource
Accession number :
edsoai.on1377970878
Document Type :
Electronic Resource